Phase 2 Hepatitis B Trial, Recruiting NCT07137910 Sponsor: Ausper Biopharma Co., Ltd. Condition: Hepatitis B
Back to Hepatitis B

Phase 2 Hepatitis B Trial, Recruiting

NCT07137910
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily and sign a consent form
  • People aged 18 to 65 years old (including those who are exactly 18 or 65)
  • People whose body weight relative to their height falls within the range required by the trial
  • People who have had chronic hepatitis B (a long-term liver infection) with specific markers detectable in their blood for at least 6 months
  • People whose previous medications meet the trial's specific requirements
  • People whose hepatitis B blood markers and liver function test results fall within the levels required by the trial
  • People who are using an effective method of contraception as specified by the trial

Who may not be able to join:

  • People who have significant health conditions, other than chronic hepatitis B, that are not stable or well-controlled
  • People who have other liver diseases in addition to hepatitis B
  • People who have a serious infection (other than hepatitis B) that requires antibiotic or antiviral treatment given through a drip or IV
  • People whose blood tests show positive results for hepatitis C, HIV, or syphilis
  • People whose laboratory (blood or urine) test results fall outside the ranges acceptable to the trial
  • People who have conditions involving inflammation of blood vessels
  • People who have an abnormal heart rhythm reading on an ECG, specifically related to a measurement called the corrected QT interval (confirm with trial site)
  • People who have had cancer in the past, or who are currently being assessed for a possible cancer diagnosis
  • People who have a history of significant allergies or are considered to have a tendency toward allergic reactions
  • People who have recently experienced a major injury or surgery, or who are planning to have surgery during the trial period
  • People who are currently in another clinical trial, or who have not completed the required waiting period after a previous trial
  • People who are currently taking, or have previously taken, medications that are not permitted under this trial's rules
  • People considered unsuitable for the trial based on the overall judgment of the medical team running the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Junqi Niu, The First Hospital of Jilin University

Phone: 0571-86959519

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ausper Biopharma Co., Ltd.
Registry
ClinicalTrials.gov
Start date
4 September 2025
Est. completion
12 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov